SCHEMBL30983918

SCHEMBL30983918

CC1(Oc2ncnc(NCc3cccc(Cl)c3)c2N)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 2/20 0.49
▸ RAF1 P04049 1/20 0.49
▸ HTT P42858 1/20 0.49
▸ PDE5A O76074 1/20 0.47
▸ CDC7 O00311 1/20 0.47
▸ DBF4 Q9UBU7 1/20 0.47
▸ EGFR P00533 3/20 0.46
▸ CDK1 P06493 3/20 0.46
▸ SRC P12931 1/20 0.46
▸ ACACB O00763 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ ABL1 P00519 2/20 0.43
▸ MAP4K4 O95819 1/20 0.43
▸ MAPT P10636 1/20 0.42
▸ APP P05067 1/20 0.42
▸ CLK4 Q9HAZ1 1/20 0.42
▸ ADORA2A P29274 3/20 0.42
▸ ADORA1 P30542 3/20 0.42
▸ ADORA3 P0DMS8 2/20 0.42
▸ KDM4C Q9H3R0 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30983865 0.86 EGFR (0.44) MAPK1HTTEGFRCDK1SMN1; SMN2
SCHEMBL31269026 0.83 CA1 (0.46) MAPK1RAF1HTTPDE5ACDC7
SCHEMBL30983996 0.77 MAPK1 (0.46) MAPK1HTTEGFRSMN1; SMN2MAPT
SCHEMBL30983842 0.73 KDM4C (0.46) HTTSMN1; SMN2KDM4C
SCHEMBL30983967 0.72 RECQL (0.42) MAPK1HTTEGFRSMN1; SMN2MAPT
SCHEMBL30984051 0.71 TAAR1 (0.38) MAPK1CDK1
SCHEMBL31321978 0.71 TAAR1 (0.38) MAPK1CDK1
SCHEMBL30984026 0.71 TAAR1 (0.38) MAPK1CDK1
SCHEMBL30983904 0.70 KCNH2 (0.38) MAPK1RAF1HTTSMN1; SMN2KDM4C
SCHEMBL11110180 0.69 CDC7 (0.56) MAPK1RAF1HTTPDE5ACDC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4689155-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS Astrazeneca AB (SE) 2026-02-11 — — EP disclosed
EP-4630410-A1 POLQ INHIBITORS Astrazeneca AB (SE) 2025-10-15 — — EP disclosed
WO-2024201368-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS ASTRAZENECA AB (SE) 2024-10-03 — — WO disclosed
WO-2024121753-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2024-06-13 — — WO disclosed
Send feedback